Twist Bioscience (NASDAQ:TWST) Releases Earnings Results, Misses Expectations By $0.10 EPS

Twist Bioscience (NASDAQ:TWST - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10), Zacks reports. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience updated its Q3 2025 guidance to EPS and its FY 2025 guidance to EPS.

Twist Bioscience Trading Up 4.1 %

Shares of TWST opened at $39.24 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience has a 52-week low of $33.16 and a 52-week high of $60.90. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of -11.61 and a beta of 2.54. The business's fifty day moving average is $39.24 and its 200-day moving average is $44.06.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 2,402 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $98,265.82. Following the sale, the chief executive officer now owns 662,692 shares in the company, valued at $27,110,729.72. This trade represents a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert Chess sold 2,940 shares of the company's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $53.13, for a total transaction of $156,202.20. Following the transaction, the director now owns 18,173 shares of the company's stock, valued at $965,531.49. This trade represents a 13.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,137 shares of company stock valued at $530,112 over the last ninety days. 3.01% of the stock is owned by corporate insiders.

Analyst Ratings Changes

TWST has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Barclays cut their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Guggenheim set a $50.00 target price on shares of Twist Bioscience in a report on Friday, March 28th. Finally, Robert W. Baird boosted their price target on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $52.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.